Drug Trial Radar · NCT03917472
Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
Last checked: Nov 20, 2026Latest source record: Aug 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
517
Actual
Start
Jul 17, 2019
Primary completion
Mar 24, 2021
Study completion Mar 24, 2021
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 17, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the efficacy and safety of brolucizumab vs. aflibercept in the treatment of patients with visual impairment due to diabetic macular edema (DME).
Conditions
- Diabetic Macular Edema
Interventions
BrolucizumabDrug
Intravitreal injection
AfliberceptDrug
Intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52Time frame: Baseline, Week 52
Locations
92 sites in 5 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Tucson, Arizona
Novartis Investigative Site
Beverly Hills, California
Novartis Investigative Site
Campbell, California
Novartis Investigative Site
Fresno, California
Novartis Investigative Site
Huntington Beach, California
Novartis Investigative Site
Loma Linda, California
Novartis Investigative Site
Mountain View, California
Novartis Investigative Site
Oakland, California
Novartis Investigative Site
Pasadena, California
Novartis Investigative Site
Poway, California
Novartis Investigative Site
Rancho Cordova, California
Novartis Investigative Site
Redlands, California
Novartis Investigative Site
Riverside, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
San Francisco, California
Novartis Investigative Site
Santa Ana, California
Novartis Investigative Site
Santa Barbara, California
Novartis Investigative Site
Torrance, California
Novartis Investigative Site
Ventura, California
Novartis Investigative Site
Altamonte Springs, Florida
Novartis Investigative Site
Deerfield Beach, Florida
Novartis Investigative Site
Fort Lauderdale, Florida
Novartis Investigative Site
Fort Myers, Florida
Novartis Investigative Site
Orlando, Florida
Novartis Investigative Site
Pinellas Park, Florida
Novartis Investigative Site
St. Petersburg, Florida
Novartis Investigative Site
Tampa, Florida
Novartis Investigative Site
Atlanta, Georgia
Novartis Investigative Site
Marietta, Georgia
Novartis Investigative Site
‘Aiea, Hawaii
Novartis Investigative Site
Bloomington, Illinois
Novartis Investigative Site
Oak Forest, Illinois
Novartis Investigative Site
Springfield, Illinois
Novartis Investigative Site
Indianapolis, Indiana
Novartis Investigative Site
New Albany, Indiana
Novartis Investigative Site
West Des Moines, Iowa
Novartis Investigative Site
Leawood, Kansas
Showing 40 of 92 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.